- Home
- FBRT vs MLYS Comparison
FBRT vs MLYS Comparison
Compare FBRT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRT
- MLYS
- Stock Information
- Founded
- FBRT 2012
- MLYS 2019
- Country
- FBRT United States
- MLYS United States
- Employees
- FBRT N/A
- MLYS N/A
- Industry
- FBRT Real Estate Investment Trusts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- FBRT Real Estate
- MLYS Health Care
- Exchange
- FBRT Nasdaq
- MLYS Nasdaq
- Market Cap
- FBRT 918.2M
- MLYS 890.6M
- IPO Year
- FBRT 1985
- MLYS 2023
- Fundamental
- Price
- FBRT $11.40
- MLYS $37.01
- Analyst Decision
- FBRT Strong Buy
- MLYS Strong Buy
- Analyst Count
- FBRT 5
- MLYS 6
- Target Price
- FBRT $14.90
- MLYS $42.60
- AVG Volume (30 Days)
- FBRT 374.9K
- MLYS 2.6M
- Earning Date
- FBRT 11-03-2025
- MLYS 11-10-2025
- Dividend Yield
- FBRT 12.33%
- MLYS N/A
- EPS Growth
- FBRT 18.52
- MLYS N/A
- EPS
- FBRT 0.98
- MLYS N/A
- Revenue
- FBRT $207,768,000.00
- MLYS N/A
- Revenue This Year
- FBRT $28.21
- MLYS N/A
- Revenue Next Year
- FBRT $2.40
- MLYS N/A
- P/E Ratio
- FBRT $11.76
- MLYS N/A
- Revenue Growth
- FBRT 16.05
- MLYS N/A
- 52 Week Low
- FBRT $9.79
- MLYS $8.24
- 52 Week High
- FBRT $13.74
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- FBRT 54.52
- MLYS 85.99
- Support Level
- FBRT $11.58
- MLYS $35.00
- Resistance Level
- FBRT $11.68
- MLYS $39.20
- Average True Range (ATR)
- FBRT 0.17
- MLYS 2.55
- MACD
- FBRT -0.02
- MLYS 1.70
- Stochastic Oscillator
- FBRT 32.03
- MLYS 91.00
About FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.